Business
Media
Conferences
Publications
CME/CE
Resources
Subscribe

Opinion|Videos|July 19, 2024

The Impact of MRI-Guided Biopsy in Diagnosis and Treatment Decisions

Author(s)Kyrollis Attalla, MD

Kyrollis Attalla, MD, shares his approach to imaging and biopsy in the diagnosis of prostate cancer and discusses the benefit of a good biopsy followed by appropriate imaging at initial diagnosis.

Episodes in this series

A panel of 4 experts on prostate cancer

EP. 1 The Role of Imaging in Diagnosing and Staging Prostate Cancer

A panel of 4 experts on prostate cancer

EP. 2 Advances in Prostate Biopsy

A panel of 4 experts on prostate cancer

EP. 3 Benefits of Incorporating Fusion-Guided Biopsy into Practice

A panel of 4 experts on prostate cancer

EP. 4 A Review of the Data for Fusion-Based Biopsy Procedures

A panel of 4 experts on prostate cancer

EP. 5 Understanding Differences in Fusion-Guided Biopsy Technologies

A panel of 4 experts on prostate cancer

EP. 6 The Role for Systematic Biopsy Plus MRI-Targeted Procedures

A panel of 4 experts on prostate cancer

EP. 7 Fusion-Guided Biopsies in Active Surveillance for Patients With Prostate Cancer

A panel of 4 experts on prostate cancer

EP. 8 Using Fusion-Guided Biopsy to Determine Eligibility for Focal Therapy

A panel of 4 experts on prostate cancer

EP. 9 Incorporating Fusion-Guided Biopsy to Practice

A panel of 4 experts on prostate cancer

EP. 10 Future Directions for Imaging and Biopsy in Prostate Cancer

Kyrollis Attalla, MD, an expert on prostate cancer

EP. 11 The Impact of MRI-Guided Biopsy in Diagnosis and Treatment Decisions

Kyrollis Attalla, MD, an expert on prostate cancer

EP. 12 Overcoming Limitations of Traditional Biopsies with MRI-Guided Biopsies

Kyrollis Attalla, MD, an expert on prostate cancer

EP. 13 An Overview of Fusion-Guided Systems

Kyrollis Attalla, MD, an expert on prostate cancer

EP. 14 Fusion-Based Biopsies in Active Surveillance

EP. 15 Expert Insights on MRI-US Fusion-Guided Biopsy

Kyrollis Attalla, MD, an expert on prostate cancer

EP. 16 The Impact of Fusion-Guided Biopsy on Focal Therapy in Prostate Cancer

Kyrollis Attalla, MD, an expert on prostate cancer

EP. 17 Looking Ahead: Image-Guided Diagnostic Tools

Video content above is prompted by the following questions:

Can you please share your approach to imaging and biopsy in the diagnosis of prostate cancer?
- What is the role of a good biopsy followed by the right imaging when a patient is first diagnosed with prostate cancer?
- How can these aid in guiding treatment decisions and ensuring best outcomes for patients?

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

Related Content

Sean P. Collins, MD, PhD, outlines the impact of rectal spacers for men with prostate cancer

BySean P. Collins, MD, PhD

November 13th 2025

Dual targeting of PAM and AR pathways yields encouraging results in mCRPC

ByAlice Bernard-Tessier, MD

November 13th 2025

Prostate cancer cells | Image Credit: © Dr_Microbe - stock.adobe.com

MRI, myths, and precision: Stacy Loeb, MD, discusses modern prostate cancer screening

ByStacy Loeb, MD, MSc, PhD (Hon)

November 12th 2025

Conceptual image for prostate cancer treatment, 3D illustration showing destruction of a tumor inside prostate gland | Image Credit: © Dr_Microbe - stock.adobe.com

Theranostic therapies expand frontline use in prostate cancer

ByJ. Travis Mendel, MD

November 11th 2025

BioProtect Balloon Spacer shows sustained quality-of-life benefits in long-term study

ByHannah Clarke

November 11th 2025

Latest CME

Community Oncology Connections™: Beyond the Basics—Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies | South Carolina

Community Oncology Connections™: Beyond the Basics—Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies | South Carolina

Scott T. Tagawa, MD, MS, FACP, FASCO; Anusha Madadi, MD

Community Oncology Connections™: Beyond the Basics—Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies | West Virginia

Community Oncology Connections™: Beyond the Basics—Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies | West Virginia

Jeremie Calais, MD, PhD; Jason Zhu, MD

Community Oncology Connections™: Beyond the Basics—Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies | Tennessee

Community Oncology Connections™: Beyond the Basics—Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies | Tennessee

Nasfat Shehadeh, MD; Jeremie Calais, MD, PhD

DSUI Urology on the Beach

In-Person Event

DSUI Urology on the Beach

January 16-18, 2026

Case-by-Case: Application of HIF-PHIs for the Treatment of Anemia in Patients With CKD

Case-by-Case: Application of HIF-PHIs for the Treatment of Anemia in Patients With CKD

Glenn M. Chertow, MD, MPH; Anil K. Agarwal, MD, FACP, FASN, FNKF, FASDIN; Preethi Yerram, MD

Medical Crossfire® in Adjunctive Testing: Charting a New Course in Prostate Cancer Risk Assessment

Medical Crossfire® in Adjunctive Testing: Charting a New Course in Prostate Cancer Risk Assessment

Jason Hafron, MD; Aaron D. Berger, MD; Arpeet Shah, MD

Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified

Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

Working Together: Overcoming Barriers to Optimize Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary Care

Working Together: Overcoming Barriers to Optimize Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary Care

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Nerina McDonald, MSPAS, PA-C; Scott T. Tagawa, MD, MS, FACP, FASCO

Radioligand Therapy 101: The Science Behind the Strategy

Radioligand Therapy 101: The Science Behind the Strategy

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

BURST CME™ Resource Center: Integrating Novel PSMA-Directed Radioligand Approaches for Diagnosis and Management of Prostate Cancer

BURST CME™ Resource Center: Integrating Novel PSMA-Directed Radioligand Approaches for Diagnosis and Management of Prostate Cancer

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Nerina McDonald, MSPAS, PA-C; Scott T. Tagawa, MD, MS, FACP, FASCO

Community Practice Connections™: Beyond the Basics— Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies

Community Practice Connections™: Beyond the Basics— Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies

Jeremie Calais, MD, PhD; Scott T. Tagawa, MD, MS, FACP, FASCO

Enhancing Prostate Cancer Outcomes – The Role of PSMA and Targeted Treatment Strategies

Enhancing Prostate Cancer Outcomes – The Role of PSMA and Targeted Treatment Strategies

Ana Kiess, MD, PhD; Erin Grady, MD, CCD, FACNM, FSNMMI; Himanshu Nagar, MD, MS; Scott T. Tagawa, MD, MS, FASCO, FACP

Guiding Prostate Cancer Diagnosis with Biomarker Testing

Guiding Prostate Cancer Diagnosis with Biomarker Testing

Aaron D. Berger, MD

Developing a Long-Term Monitoring Plan to Assess Prostate Cancer Risk

Developing a Long-Term Monitoring Plan to Assess Prostate Cancer Risk

Jason M. Hafron, MD

Burst CME™: Incorporating Multiparametric MRI to Guide Prostate Cancer Diagnosis

Burst CME™: Incorporating Multiparametric MRI to Guide Prostate Cancer Diagnosis

Stacy Loeb, MD, MSc, PhD (Hon)

Trending on Urology Times

MRI, myths, and precision: Stacy Loeb, MD, discusses modern prostate cancer screening

Sean P. Collins, MD, PhD, outlines the impact of rectal spacers for men with prostate cancer

Dual targeting of PAM and AR pathways yields encouraging results in mCRPC

Suzanne Merrill, MD, on integrating ICIs into clinical practice for NMIBC

Health Canada approves testosterone undecanoate for hypogonadism

© 2025 MJH Life Sciences^®

All rights reserved.